Trial reportClinical pharmacokinetics2004
Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
Trial report in Clinical pharmacokinetics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- Anemia in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Review
- Chronic kidney disease in children.Clinical kidney journal · 2016Article
- Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2014Review
- Anemia in children with chronic kidney disease.Nature reviews. Nephrology · 2011Review
- Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.Pediatric nephrology (Berlin, Germany) · 2009Article
- Hemoglobin target in chronic kidney disease: a pediatric perspective.Pediatric nephrology (Berlin, Germany) · 2009Article
- Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit?Pediatric nephrology (Berlin, Germany) · 2009Article
- Anemia in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2008Review
- Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?BMC nephrology · 2006Article
- Drug dosage in children with reduced renal function.Pediatric nephrology (Berlin, Germany) · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug doses for children are usually calculated by reducing adult doses in proportion to bodyweight. The clinically effective dose of recombinant human erythropoietin (epoetin) in children, however, seems to be higher than predicted by this calculation.
objectiveTo determine the quantitative relationship between epoetin dose, bodyweight and response in children with end-stage renal disease. PATIENTS AND
methodsThe time-course of haemoglobin in 52 children during long-term treatment with epoetin beta was analysed by population pharmacodynamic modelling. Patients were 5-20 years old and weighed 16-53kg at the beginning of treatment. Epoetin beta was given intravenously three times per week after haemodialysis. Doses ranged from 110 to 7500IU (3-205 IU/kg). Haemoglobin versus time was described by assuming that the haemoglobin level rises after each dose due to the formation of new red blood cells, which then survive according to a logistic function. The initial rise after each dose was modelled in terms of absolute dose (not dose/kg). A parametric analysis was done with NONMEM, followed by a nonparametric analysis with NPAG.
resultsDose-response was best described by a sigmoid maximum-effect (E(max)) model with median E(max) = 0.29 g/dL, median 50% effective dose (ED(50)) = 2400IU and shape parameter gamma = 2. The estimated median survival time of the epoetin-induced red blood cells, tau, was 76 days. Neither of the dose-response parameters E(max) and ED(50) showed dependence on bodyweight. The median haemoglobin response to a standard dose, 0.042 g/dL for 1000IU, was similar to that reported for adults with intravenous administration.
conclusionsDoses for children in this age range should be specified as absolute amounts rather than amounts per unit bodyweight. Initial doses can be calculated individually, based on haemoglobin level before treatment, the desired haemoglobin at steady state and the median population parameters E(max), ED(50) and tau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.